Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares,
Neurocrine Biosciences chief scientific officer sells $336,238 in stock
Onyia Jude, Chief Scientific Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently executed stock transactions involving the company's common shares. According to a recent SEC filing, Jude sold a total of 2,
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 million compared to $515.
Neurocrine Biosciences (NASDAQ:NBIX) Raised to Strong-Buy at StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A number of other analysts have also recently issued reports on the company.
UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating
UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118.
Neurocrine stock target cut to $185 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $185 from the previous $190 while maintaining a Buy rating on the stock. This revision follows the company's announcement yesterday that Ingrezza,
Neurocrine Biosciences CHRO sells shares worth $181,129
Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold company shares valued at $181,129. The transactions, executed on February 13, 2025, involved the ...
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...
FiercePharma4d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...